Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:27:10 EDT Sat 05 Jul 2025
Enter Symbol
or Name
USA
CA



Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q1.069.46·69.610.969.45-1.68-2.46,768.071.11  71.16  69.1887.67  61.24Jul 03Jun 2415 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 07:00U:AZNNews ReleaseDATROWAY(TM) approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-02 08:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
2025-06-01 08:05U:AZNNews ReleaseIMFINZI(TM) (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
2025-06-01 08:00U:AZNNews ReleaseCamizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-05-21 07:00U:AZNNews ReleaseAstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
2025-05-19 12:34U:AZNNews ReleaseStatistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
2025-05-13 07:00U:AZNNews ReleaseAstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
2025-05-09 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
2025-05-07 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
2025-05-02 07:00U:AZNNews ReleaseBREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
2025-04-29 02:00U:AZNNews ReleaseAstraZeneca's Q1 2025 Financial Results
2025-04-21 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
2025-03-31 12:00U:AZNNews ReleaseAZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
2025-03-31 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
2025-03-25 19:02U:AZNNews ReleaseNew study results reinforce TAGRISSO(TM) (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
2025-03-14 12:00U:AZNNews ReleaseAstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
2025-03-07 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
2025-03-01 17:30U:AZNNews ReleasePositive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
2025-02-26 07:00U:AZNNews ReleaseCamizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-02-14 11:10U:AZNNews ReleaseIMFINZI(TM) (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial